ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 829

Subcutaneous Nodules Are Significantly Associated with Cardiovascular Events in Patients with Rheumatoid Arthritis: Results From a Very Large US Registry

Prashant Kaushik1, Susan P. Messing2, Jyoti Arora2, George Reed3, Katherine C. Saunders4, Jeffrey D. Greenberg5 and Joel M. Kremer6, 1Department of Medicine, Sratton VAMC, Albany, NY, 2Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 3Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, 4Corrona, LLC., Southborough, MA, 5New York Hospital for Joint Disease, New York, NY, 6Albany Medical College and The Center for Rheumatology, Albany, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Cardiovascular Disease (CVD) is now recognized to be a major comorbidity of patients with rheumatoid arthritis.  Predictors of CVD have been shown to include a variety of measures of RA disease activity and severity (1). Although subcutaneous nodules (SQN) are associated with more severe RA, until this time there had been no clinical phenotypic characteristic which was immediately recognizable as a marker of increased risk for CVD in patients with RA.

Methods:

Data are from the CORRONA database from Oct 2001 to Sept 2011 was evaluated.  23327 patients with RA, including 182,201 individual visits who have an average of 3 years of follow-up data  and with 70455 patient-years and 795 CV events are included in this analysis.   Presence or absence of SCN have been routinely collected over the entire 11 year history of the registry.  CV events (ischemic heart disease including MI, stroke/TIA, CHF and CV death ) were defined by MD reported events and exclusion of events not confirmed by the sites completing a follow up form.  Cox regression models were used to estimate HR for time to first event with entry into CORRONA as the origin.  Unadjusted and adjusted Hazard Ratios (HR) for SCN were estimated.   A multivariable model was fit that considered the following factors as possible covariates: age, gender, age of onset of RA, presence of diabetes mellitus (DM), hypertension, smoking, alcohol consumption,  use of a lipid lowering agent.  Significant factors were retained in the model.

Results:  

Table 1 shows the estimated HR for SCN unadjusted and then adjusted with the covariates considered in the model.   Unadjusted HR for SCN is 1.44, 95% CI: [1.23-1.67].  Adjusted HR is 1.25 [1.07-1.46]. An interaction of age and gender provided a better fit of the model, females with a steeper increase in risk with age than males. 

Conclusion:

We report for the first time, from a very large US observational registry, that SCN confer a significantly increased likelihood of CVD in patients with RA followed for a period of > 3 years.  While active RA is a risk factor for CVD the presence of subcutaneous nodules, an immediately assessable and accessible clinical phenotype, confers an increased risk for this major comorbidity.

1             Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69(11):1920-5.

 

Table 1. CV risk associated with subcutaneous nodules adjusted and unadjusted Hazard Ratios (HR)

 

HR

95% CI

p-value

Subcutaneous Nodules (unadjusted)

1.44

[1.23-1.67]

<0.0001

Multivariable Model

    Subcutaneous Nodules

1.25

[1.07-1.46]

0.0048

    History of CVD

2.89

[2.40, 3.48]

<0.0001

    Diabetes

1.72

[1.40,2.10]

<0.0001

    Hx of Hypertension

1.47

[1.25, 1.73]

<0.0001

    Current Smoker

1.39

[1.16, 1.66]

0.0003

    Current Drinker

0.74

[0.63, 0.86]

0.0002

    Age Onset of RA (per year)

1.004

[1.001, 1.007]

0.121

    Lipids Measured

1.65

[1.21, 2.23]

0.0014

    Age (Males)*  (per year)

1.01

[1.00, 1.02]

0.049*

    Age (Females)* (per year)

1.03

[1.02, 1.04]

    Females vs Males (at age 40)*

0.39

[0.26, 0.60]

    Females vs Males (at age 70)*

0.59

[0.50, 0.70]

 

      *Age-Gender interaction included in the model; p-value for test of interaction.

 


Disclosure:

P. Kaushik,
None;

S. P. Messing,
None;

J. Arora,

University of Rochester,

3;

G. Reed,

Corrona,

5,

Corrona,

2;

K. C. Saunders,

Corrona,

3;

J. D. Greenberg,

Corrona,Inc.,

1,

Astra Zeneca, Corrona, inc. Novartis, Pfizer,

5;

J. M. Kremer,

Pfizer Inc, BMS, Genentech, HGS, UCB,

2,

Pfizer Inc, Amgen, Abbott, Genentech,

5,

Corrona,

4,

abbott, Amgen, BMS ,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-nodules-are-significantly-associated-with-cardiovascular-events-in-patients-with-rheumatoid-arthritis-results-from-a-very-large-us-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology